|
|
||||||||
B and Enhances Tumor Cell Adhesion and Invasion Through a
1 Integrin-Dependent Mechanism

* Department of Academic Surgery, National University of Ireland, Cork University Hospital, Cork, Ireland; and
Department of Academic Surgery, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland
| Abstract |
|---|
|
|
|---|
1 integrins play a crucial role in
supporting tumor cell attachment to and invasion into the extracellular
matrix. Endotoxin/LPS introduced by surgery has been shown to enhance
tumor metastasis in a murine model. Here we show the direct effect of
LPS on tumor cell adhesion and invasion in extracellular matrix
proteins through a
1 integrin-dependent pathway. The
human colorectal tumor cell lines SW480 and SW620 constitutively
expressed high levels of the
1 subunit, whereas various
low levels of
1,
2,
4, and
6 expression were detected. SW480 and SW620 did not
express membrane-bound CD14; however, LPS in the presence of soluble
CD14 (sCD14) significantly up-regulated
1 integrin
expression; enhanced tumor cell attachment to fibronectin, collagen I,
and laminin; and strongly promoted tumor cell invasion through the
Matrigel. Anti-
1 blocking mAbs (4B4 and 6S6) abrogated
LPS- plus sCD14-induced tumor cell adhesion and invasion. Furthermore,
LPS, when combined with sCD14, resulted in NF-
B activation in both
SW480 and SW620 cells. Inhibition of the NF-
B pathway significantly
attenuated LPS-induced up-regulation of
1 integrin
expression and prevented tumor cell adhesion and invasion. These
results provide direct evidence that although SW480 and SW620 cells do
not express membrane-bound CD14, LPS in the presence of sCD14 can
activate NF-
B, up-regulate
1 integrin
expression, and subsequently promote tumor cell adhesion and invasion.
Moreover, LPS-induced tumor cell attachment to and invasion through
extracellular matrix proteins is
1
subunit-dependent. | Introduction |
|---|
|
|
|---|
Integrins are the most important family of cell surface adhesion
molecules that mediate interactions between cells and the extracellular
matrix (5). They are heterodimeric transmembrane receptors
consisting of
and
subunits. Each subunit is a glycoprotein with
a large extracellular domain and a relatively small cytoplasmic domain.
The different integrin subfamilies are determined by the
subunit;
for example, the
1 subunit associates with
different
subunits to form the
1 integrin
subfamily. To date >20 different integrin heterodimers are known,
which bind to specific ligands present in the extracellular matrix or
expressed on target cells. Members of the
1
integrin subfamily primarily bind to components of the extracellular
matrix, such as fibronectin, collagens, and laminins, but some of them
also participate in direct cell-to-cell adhesion (5, 6).
Among the different integrin heterodimers,
1
and
3 integrins appear to play a crucial role
in regulating tumor cell proliferation, differentiation, adhesion,
motility, and invasion (7, 8). Increased expression of
different members of the
1 integrin has been
found to be associated with tumor cell survival, invasion, and tumor
progression. Up-regulation of
2
1 integrin
expression enhances tumor cell adhesion and prevents high dose
epidermal growth factor-induced cell death (9).
Overexpression of the
3 subunit of
1 integrin in the MDA-MB-231 breast carcinoma
cell line is associated with the potent migratory and invasive
properties of these cells, which is strongly inhibited by a specific
function-blocking anti-
3 mAb
(10). Using a targeted elimination technique, it has been
found that the expression of integrin
6
1 in MDA-MB-435
breast carcinoma cell line is essential for facilitating tumorigenesis
and promoting tumor cell survival in distant organs in mice
(11). Overexpression of
6 subunit
of the
1 integrin has been found in human
hepatocellular carcinoma with aggressive phenotypes (12).
Recently, it has been shown that organ-specific sites of metastatic
lesions are determined at least in part by
1
integrin-mediated adhesion to and invasion into the subendothelial
extracellular matrix, and furthermore, different metastatic behaviors
of tumors correlate with
1 integrin-mediated
adhesive properties (4, 13).
LPS or endotoxin, a predominant glycolipid in the outer membrane of
Gram-negative bacteria, provides a highly potent stimulus to cells of
the immune system. LPS stimulates monocytes, macrophages, and
neutrophils through the activation of transcription factors and
protein kinases such as NF-
B and p38 kinase, resulting in an
increased production of proinflammatory cytokines and overexpression of
cell adhesion molecules (14, 15). LPS-induced cellular
activation is mediated by its complexing with circulating LPS-binding
protein (LBP)2 and
subsequent binding to CD14, a 55-kDa glycosylphosphatidylinositol
(GPI) membrane-anchored glycoprotein (16, 17), which, in
turn, facilitates intracellular transduction of LPS signaling through
Toll-like receptor 4 (TLR4) (18, 19). It has been noted
that rapid growth of previously dormant metastases occurs following
surgical removal of a primary tumor (20). The mechanisms
underlying this phenomenon are not fully elucidated. Two recent studies
have shown a crucial role for LPS contamination following surgery in
tumor growth and metastases (21, 22). Both laparotomy and
air laparoscopy result in endotoxin contamination of the peritoneal
cavity and systemic endotoxemia via bacterial translocation across the
gut (21). In a murine model of metastatic disease, animals
subjected to laparotomy or air laparoscopy with high levels of
circulating LPS had increased lung metastatic burdens, whereas animals
subjected to CO2 laparoscopy with very low levels
of plasma LPS had metastatic tumor growth similar to that in controls.
Furthermore, there were significantly increased lung metastases in
animals that received an equivalent LPS injection (22).
These results indicate that LPS entering the peritoneal cavity or
systemic circulation during surgery is associated with enhanced growth
of metastases following surgical trauma. However, the direct effect of
LPS on invasive and metastatic behavior of tumor cells is unclear.
The transcription factor NF-
B is involved in the regulation of
multiple cellular processes, including proinflammatory cytokine gene
expression, cellular adhesion, cell cycle activation, apoptosis, and
oncogenesis. Currently known subunit members of the NF-
B family in
mammals are five proteins related by the Rel homology domain, namely
p50, p65 (Rel A), the proto-oncogene c-rel (c-Rel), p52, and
Rel B (23). In most cells the NF-
B heterodimer is
sequestered in the cytoplasm as an inactive form through interaction
with an inhibitory
B (I
B) protein that inhibits nuclear
translocation of NF-
B. Several I
B isoforms have been identified,
but the most extensively characterized isoforms are I
B-
,
I
B-
, and I
B-
(24). When I
B is degraded
through the phosphorylation of I
B-
induced by activated I
B
kinases, the NF-
B heterodimer will enter the nucleus, bind to the
promoter regions of the target genes, and stimulate transcription
(23, 25). It has been shown that constitutive activation
of NF-
B is present in a number of tumor cells, including
hepatocellular carcinoma cells (26), breast cancer cells
(27), and non-small cell lung cancer cells
(28). Elevated NF-
B activity in tumor cells may be
related to an overproduction of cytokines, such as vascular endothelial
growth factor (VEGF), GM-CSF, and IL-8, by tumor cells (29, 30), which may provide continued positive growth stimuli.
Constitutive activation of NF-
B has been shown to protect tumor
cells against apoptosis (31), and inhibition of NF-
B
can sensitize tumor cells to undergo chemotherapy-induced apoptosis
(28, 32), indicating a role for NF-
B in the development
of tumor resistance to cancer treatment. A recent study has shown that
blockade of NF-
B signal in a murine lung alveolar carcinoma cell
line by transfection of a dominant negative mutant form of I
B-
that cannot be phosphorylated prevents intravasation of tumor cells in
an in vivo chick embryo metastasis model and lung metastasis in a
murine model (33), suggesting that activation of NF-
B
plays a central and specific role in the regulation of tumor
metastasis.
In the present study we examined the effects of LPS on
1 integrin expression and subsequent tumor
cell adhesion to and invasion into the extracellular matrix. We also
investigated the effects of LPS on NF-
B activation and its relation
to tumor cell invasive behavior. Here we provide evidence for the first
time that LPS directly enhances tumor cell invasive and metastatic
potentials. Using two human colorectal tumor cell lines, SW480 and
SW620, cultured in an in vitro serum-free culture system, this report
shows that LPS in the presence of soluble CD14 (sCD14) can up-regulate
1 integrin expression and promote tumor cell
adhesion and invasion through a
1
integrin-dependent mechanism. Furthermore, LPS can directly activate
NF-
B in SW480 and SW620 tumor cells. Blockade of NF-
B activation
prevents LPS-induced
1 integrin overexpression
and attenuates tumor cell adhesion and invasion, indicating a key role
for NF-
B activation in transducing LPS signaling and subsequent
LPS-promoted tumor cell adhesion and invasion.
| Materials and Methods |
|---|
|
|
|---|
Medium 199, medium L-15, HBSS, PBS without
Ca2+ and Mg2+, FCS,
penicillin, streptomycin sulfate, glutamine, and 0.05% trypsin/0.02%
EDTA solution were purchased from Life Technologies (Paisley,
Scotland). Human plasma fibronectin, collagen I from calf skin, laminin
from human placenta, LPS (Escherichia coli O55B5), HEPES,
MgCl2, KCl, NaCl, EDTA, Tris-HCl, glycerol,
nuclease-free BSA, Nonidet P-40, PMSF, and DTT were purchased from Life
Technologies and Sigma-Aldrich (St. Louis, MO), respectively.
[
-32P]ATP (3000 Ci/mmol) and poly(dI-dC)
were obtained from Amersham International (Little Chalfont, U.K.) and
Amersham Pharmacia Biotech (Milton Keynes, U.K.), respectively. SN50, a
cell-permeable peptide inhibitor of NF-
B, was purchased from
Calbiochem (San Diego, CA). Recombinant human sCD14 was obtained from
Biometec (Greifswald, Germany). Mouse anti-human CD14 mAb was
obtained from BD Biosciences (Mountain View, CA). Mouse anti-human
integrin
1,
1,
2,
3,
4,
5,
6, and
v
3 mAbs were
purchased from Chemicon (Temecula, CA), BD PharMingen (San Diego, CA),
and Serotec (Oxford, U.K.), respectively.
1
integrin-blocking mAbs 4B4 and 6S6 were purchased from Coulter Clone
(Miami, FL) and Chemicon, respectively.
Cell culture
Human colorectal tumor cell lines SW480 and SW620 were obtained from American Type Culture Collection (Manassas, VA). SW480 and SW620 cells were grown in medium L-15 supplemented with 10% FCS, penicillin (100 U/ml), streptomycin sulfate (100 µg/ml), and glutamine (2.0 mM). Cells were maintained at 37°C in a humidified 5% CO2 atmosphere and subcultured by trypsinization with 0.05% trypsin/0.02% EDTA when cells became confluent. After the second passage, SW480 and SW620 cells were incubated in an in vitro serum-free culture system in all experiments conducted in this study.
FACS analysis of immunofluorescence
SW480 and SW620 cells cultured in serum-free medium were exposed
to LPS alone (0.1 µg/ml) or a combination of LPS (0.1 µg/ml) and
sCD14 (0.2 µg/ml) for 4 h at 37°C in humidified 5%
CO2 conditions. The expression of different
subunits of
1 integrins,
v
3, and
membrane-bound CD14 (mCD14) on SW480 and SW620 cells was determined
using direct and indirect immunofluorescent staining. For direct
immunofluorescent staining, 20 µl of FITC-conjugated
anti-integrin
5 (anti-CD49e),
FITC-conjugated anti-integrin
v
3
(anti-CD51/61), FITC-conjugated anti-Leu M3 (anti-CD14),
PE-conjugated anti-integrin
4
(anti-CD49d), and PE-conjugated anti-integrin
1 (anti-CD29) mAbs were added to 100 µl
of cell suspension (1 x 106 cells/ml) and
incubated at 4°C for 30 min. FITC- and PE-conjugated isotype IgG1 and
IgG2b mAbs were used as negative controls. For indirect
immunofluorescent staining, 100 µl of cell suspension (1 x
106 cells/ml) was incubated with 20 µl of pure
mAbs against integrin
1 (anti-CD49a),
integrin
2 (anti-CD49b), integrin
3 (anti-CD49c), and integrin
6 (anti-CD49f) at 4°C for 30 min and
further stained with secondary FITC-conjugated mAb at 4°C for 30 min.
Pure isotype IgG1 mAb was used as a negative control. Different
1 integrins,
v
3, and mCD14
expression on SW480 and SW620 cells were analyzed on a FACScan flow
cytometer (BD Biosciences) for detecting the log of the mean channel
fluorescence intensity with an acquisition of FL1 and FL2,
respectively. A minimum of 10,000 events were collected and analyzed on
CellQuest software (BD Biosciences).
Tumor cell adhesion
Tumor cell attachment to fibronectin, collagen I, and laminin
was performed as previously described (34) with some
modifications. Briefly, fibronectin (2.0 µg/ml), collagen I (1.5
µg/ml), and laminin (3.5 µg/ml) were coated onto 96-well,
flat-bottom, microtiter plates (Falcon, Lincoln Park, NJ). SW480 and
SW620 cells cultured in serum-free medium were treated with LPS alone
(0.1 µg/ml) or LPS plus sCD14 (0.1 and 0.2 µg/ml) for 4 h at
37°C in humidified 5% CO2 conditions. For
1 integrin and NF-
B blocking experiments,
cells were treated with different mAbs or SN50 for 30 min before being
exposed to LPS or LPS plus sCD14. Cells (5 x
104 cells/ml) were then added to the
fibronectin-, collagen I-, and laminin-coated 96-well plates and
incubated at 37°C in humidified 5% CO2
conditions for 1 h. The plate was washed twice with HBSS to remove
unbound cells. Tumor cell adhesion to fibronectin, collagen I, and
laminin was assessed using CellTite 96 Aqueous One Solution Assay
(Promega, Madison, WI) on a Microtiter Plate Reader (Dynex
Technologies, Chantilly, VA). The specific absorbance at 490 nm
generated from CellTite 96 Aqueous One Solution Assay is directly
proportional to the number of adherent cells in the plate. The ratio of
the percentage of adherent tumor cells to that of total added tumor
cells was calculated according to the following formula:
![]() |
Tumor cell invasion
In vitro tumor cell invasion was assessed using a Biocoat
Matrigel invasion chamber (BD Biosciences) with cell culture inserts
containing an 8-µm pore size positron emission tomography membrane
with a thin layer of Matrigel basement membrane matrix as previously
described (35, 36). Briefly, 0.5 ml of tumor cells (1
x 105 cells/ml) resuspended in serum-free medium
containing either LPS alone (0.1 µg/ml) or LPS plus sCD14 (0.1 and
0.2 µg/ml) was added to the cell culture insert of a Biocoat Matrigel
invasion chamber. Fibronectin (20 µg/ml) was added in the outer
chamber as a chemoattractant. The cells were then incubated at 37°C
in humidified 5% CO2 conditions for 18 h.
To quantitative tumor cell invasion, noninvading cells were removed
from the upper surface of the membrane by scrubbing gently with a
cotton-tipped swab. The cells on the lower surface of the membrane were
fixed with Rapi-Diff II (DiaChem, Lancashire, U.K.). Five random
microscope fields of the lower surface of the membrane were counted for
numbers of cells that had invaded through the Matrigel layer and the
membrane. The results were expressed as numbers of invaded cells per
microscope field. To examine whether
1
integrins and NF-
B activation are involved in LPS-induced tumor cell
invasion, SW480 and SW620 cells were treated with different blocking
mAbs or SN50 for 30 min before being exposed to LPS alone or LPS plus
sCD14.
Transfection assays
Dual transfection of SW480 and SW620 cells was accomplished
using 16 µl/ml of Lipofectamine 2000 reagent (Life Technologies) and
4.0 µg/ml of pNF-
B-Luc vector DNA (Clontech Laboratories, Palo
Alto, CA) that contains the firefly luciferase gene as the reporter.
The pRL-CMV vector (Promega) containing the Renilla
luciferase gene was used as an internal control. Briefly, SW480 and
SW620 cells were plated in 96-well plates (Falcon; 2 x
104 cells/well) to grow at 37°C in humidified
5% CO2 conditions until they reached 9095%
confluence. Reporter DNA (0.2 µg) was mixed with 0.8 µl of
Lipofectamine in 50 µl of serum-free Opti-MEM I (Life Technologies),
and incubated at room temperature for 20 min to form Lipofectamine-DNA
complexes. Cells in 96-well plates were transfected with the complexes
for 6 h and cultured for an additional 18-h period after
replacement of the medium. Each transfection was performed in
duplicate. Transfected cells were exposed to LPS alone (0.1 µg/ml) or
LPS plus sCD14 (0.1 and 0.2 µg/ml) for 6 h. Cell extract was
prepared using the Passive lysis buffer (Promega), and protein content
in each sample was determined using a Micro BCA protein assay reagent
kit (Pierce, Rockford, IL). Firefly and Renilla luciferase
activities were measured using the Dual luciferase reporter assay
system (Promega) to assess promoter activity and transfection
efficiency.
SW480 cells were also transfected with a dominant negative I
B-
vector or an empty expression vector pcDNA3.1 as a negative control
(provided by Dr. A. G. Bowie, Trinity College, Dublin, Ireland)
(37). Briefly, SW480 cells were plated in 24-well plates
(Falcon; 1 x 105 cells/well) and grown
until they reached 9095% confluence. The vector DNA-Plus
Reagent-Lipofectamine complexes were produced by mixing dominant
negative I
B-
vector DNA (0.12 µg) or empty vector DNA (0.12
µg/ml) with 4 µl of Plus Reagent (Life Technologies) and 1 µl of
Lipofectamine (Life Technologies). Cells in 24-well plates were
transfected with the complexes for 3 h and cultured for an
additional 15-h period after replacement of the medium. Each
transfection was performed in duplicate. Expression of
1 integrin, cell adhesion, and invasion in
response to LPS plus sCD14 stimulation were assessed in the transfected
cells. Transfection efficiency, and inhibition of NF-
B activation
were assessed by dual transfection of dominant negative I
B-
vector (0.040.16 µg) in combination with pSV-
-galactosidase
vector (Promega) or pNF-
B-Luc vector (Clontech Laboratories).
Nuclear extract preparation
SW480 and SW620 cells were cultured in serum-free medium in six-well plates (Falcon; 1 x 106 cells/well) and treated with LPS alone (0.1 µg/ml) or LPS plus sCD14 (0.1 and 0.2 µg/ml) for 30 min. Nuclear and cytoplasmic extracts were prepared as previously described (38). Briefly, cells were lysed in a hypotonic solution (10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, and 0.1% Nonidet P-40, pH 7.9) on ice for 10 min and centrifuged at 13,000 rpm to pellet nuclei. Cytoplasmic supernatants were removed, and nuclei were resuspended in nuclear extract buffer (20 mM HEPES, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, and 0.2 mM EDTA, pH 8.0) on ice for 15 min. The lysates were centrifuged at 13,000 rpm, and supernatants containing the nuclear proteins were collected. All buffers contained freshly added 0.5 mM DTT, 0.5 mM PMSF, and protease inhibitor cocktail (Roche, Mannheim, Germany). Protein concentrations were determined using a Micro BCA protein assay reagent kit (Pierce). All extracts were stored at -70°C until analyzed.
Electrophoretic mobility shift assays
EMSAs were performed as previously described (39).
Briefly, 2.04.0 µg of nuclear extracts were incubated with 30,000
cpm of double-stranded oligonucleotide 5'-AGT TGA GGG GAC TTT
CCC AGG C-3' containing the NF-
B consensus sequence
(underlined; Promega) that had been previously labeled with
[
-32P]ATP (10 mCi/mmol) by T4 polynucleotide
kinase (Promega). The DNA binding reactions were performed in the
presence of 2.0 µg of poly(dI-dC) as a nonspecific competitor in
binding buffer (10 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1.0 mM EDTA, 5.0
mM DTT, 4% glycerol, and 100 µg/ml of nuclease-free BSA) at room
temperature for 30 min. For competition experiments, unlabeled
double-stranded oligonucleotide 5'-AGT TGA GGC GAC TTT CCC
AGG C-3' containing the mutated NF-
B consensus sequence (underlined;
Promega) was added to the nuclear extracts 30 min before the addition
of the radiolabeled probe. All reaction mixtures were subjected to
electrophoresis on native 5% (w/v) polyacrylamide gels, which were
subsequently dried and autoradiographed.
Statistical analysis
All data are presented as the mean ± SD. Statistical analysis was performed using ANOVA. Differences were judged statistically significant at p < 0.05.
| Results |
|---|
|
|
|---|
1 integrins,
v
3 and mCD14
As determined by FACScan analysis, human colorectal tumor cell
lines SW480 and SW620 constitutively expressed high levels of integrin
1 subunit, whereas various low levels of
integrin
1,
2, and
4 expression on SW480 and of
2,
4, and
6 expression on SW620 were also detected (Fig. 1). However, the expressions of integrin
3 and
5 subunits, and
integrin
v
3 were
almost absent in both SW480 and SW620 cells (data not shown).
Furthermore, these two tumor cell lines did not contain mCD14 (Fig. 2), the cell surface receptor of a 55-kDa
GPI membrane-anchored glycoprotein for LPS recognition and binding.
|
|
1 integrin expression by
LPS in the presence of sCD14
When tumor cells were incubated in a serum-free culture system,
LPS alone at 0.1 µg/ml had no effect on modulating
1 integrin expression. However, LPS (0.1
µg/ml) in the presence of sCD14 (0.2 µg/ml) significantly
up-regulated the expression of integrin
1,
2, and
4 subunits on
SW480 cells and the expression of integrin
1,
4, and
6 subunits on
SW620 cells (Fig. 3). LPS plus sCD14 did
not enhance integrin
1 expression on SW480 and
integrin
2 expression on SW620 cells (Fig. 3).
Soluble CD14 alone (0.2 µg/ml) did not affect the expression of
different
1 integrin subunits on these two
tumor cell lines (data not shown).
|
In the absence of exogenous stimulation, both SW480 and SW620 cells showed various levels of spontaneous adhesion to extracellular matrix proteins such as fibronectin, collagen I, and laminin (Fig. 4). Under an in vitro serum-free culture condition, SW480 and SW620 cells stimulated with LPS alone (0.1 µg/ml) did not significantly affect the attachment of tumor cells to extracellular matrix proteins (Fig. 4, A and B). When tumor cells were treated with a combination of LPS (0.1 µg/ml) and sCD14 (0.2 µg/ml), however, there were significant increases in SW480 and SW620 cell adhesion to fibronectin, collagen I, and laminin by 2- to 3-fold (p < 0.05 vs tumor cells treated with either culture medium or LPS alone; Fig. 4, A and B). To evaluate LPS-dependent tumor cell invasion in an in vitro model, we used Biocoat Matrigel chambers. As shown in Fig. 5, LPS (0.1 µg/ml) in the presence of sCD14 (0.2 µg/ml) significantly promoted SW480 and SW620 cell invasion through the Matrigel (p < 0.05 vs tumor cells treated with either culture medium or LPS alone). In contrast, when SW480 and SW620 cells were treated with LPS alone (0.1 µg/ml), no significant effects on tumor cell invasion were observed (Fig. 5).
|
|
1 in LPS-induced
tumor cell adhesion and invasion
1 integrins play a crucial role in
supporting tumor cell attachment to, migration, and invasion into
extracellular matrix proteins. To determine whether
1 integrin is involved in LPS-induced tumor
cell adhesion and invasion, we used anti-
1
integrin mAbs to selectively block integrin
1
subunits. Pretreatment of SW480 and SW620 cells with 4B4 and 6S6, two
specific integrin
1 subunit blocking mAbs,
almost totally prevented LPS plus sCD14-induced tumor cell adhesion to
fibronectin (p < 0.05 vs tumor cells treated
with LPS plus sCD14; Fig. 6).
Furthermore, 4B4 and 6S6 significantly attenuated LPS plus
sCD14-promoted SW480 and SW620 cell invasion (p
< 0.05 vs tumor cells treated with LPS plus sCD14; Fig. 6). An
isotype-matched mouse IgG1 used as the control for 4B4 and 6S6 had no
effect on LPS- plus sCD14-induced tumor cell adhesion and invasion
(Fig. 6). These results indicate that LPS-induced SW480 and SW620 cell
adhesion and invasion through extracellular matrix proteins are
1 integrin dependent.
|
B by LPS in the presence of sCD14
NF-
B activation induced by a combination of LPS and sCD14 was
assessed by transfection of SW480 cells with pNF-
B-Luc reporter
vector. As shown in Fig. 7A,
LPS in the presence of sCD14 resulted in a significant increase in
luciferase activity (p < 0.05), indicating the
activation of NF-
B following LPS and sCD14 stimulation. NF-
B-DNA
binding activity was also assayed by EMSA using nuclear extracts that
were prepared from SW480 cells incubated with serum-free culture
medium, LPS alone, sCD14 alone, or LPS plus sCD14. There was a
low level of constitutive activation of NF-
B in unstimulated cells;
however, LPS in the presence of sCD14 caused a marked activation of
NF-
B (Fig. 7B). LPS alone or sCD14 alone had no effect on
NF-
B activation. Similar levels of NF-
B activation were also
found in SW620 cells treated with LPS plus sCD14 (data not shown).
|
1 integrin
overexpression, tumor cell adhesion and invasion by a NF-
B inhibitor
SN50 or in the dominant negative I
B-
transfected cells
SN50 is a synthetic peptide containing a cell membrane-permeable
motif and nuclear trans-locating hydrophobic sequence that
inhibits nuclear translocation of NF-
B in a dose-dependent manner in
cultured endothelial and monocytic cells stimulated with LPS or TNF-
(40). In a dose-response experiment we found that
inhibition of NF-
B activation, as represented by luciferase activity
in the transfected SW480 cells by SN50 was 18% at 25 µg/ml, 62% at
50 µg/ml, 94% at 100 µg/ml, and 92% at 200 µg/ml. As shown in
Fig. 8, when SW480 cells were pretreated
with SN50 at 100 µg/ml, there was a total abrogation of up-regulation
of integrin
1,
2, and
4 expression induced by LPS plus sCD14.
Furthermore, pretreatment of SW480 cells with SN50 at 100 µg/ml
significantly attenuated LPS-induced tumor cell adhesion and invasion
(p < 0.05 vs tumor cells treated with LPS plus
sCD14; Fig. 8). SN50 at 100 µg/ml was not toxic to the cells as
determined by measurement of lactate dehydrogenase release and did not
affect cell viability as determined by trypan blue exclusion and
propidium iodide staining on flow cytometry (data not shown).
|
B-
vector lacks both constitutive and
inducible phosphorylation sites and does not dissociate from NF-
B in
response to stimulation of the I
B kinase pathways (41).
Thus, dominant negative I
B-
vector can be used to eliminate
NF-
B activation and to block the NF-
B signal transduction pathway
in the transfected cells. As shown in Fig. 9, FACScan analysis of
1 integrin expression on SW480 cells
demonstrated a significant attenuation of LPS plus sCD14-induced
integrin
1,
2, and
4 overexpression in dominant negative
I
B-
transfected cells. Transfection of SW480 cells with dominant
negative I
B-
vector also prevented the increased tumor cell
attachment to fibronectin and invasion in Matrigel in response to LPS
plus sCD14 stimulation. In contrast, transfection with empty vector
showed no effect on LPS- plus sCD14-stimulated
1 integrin expression, tumor cell adhesion,
and invasion (Fig. 9).
|
| Discussion |
|---|
|
|
|---|
In the present study SW480 and SW620 cells did not express mCD14, as
confirmed by FACScan analysis. To identify a critical role for
CD14 in LPS-induced cellular responses in tumor cells, we have employed
an in vitro serum-free culture system to eliminate the influences of
sCD14 and other soluble factors, such as LBP, that are present in the
serum. Results obtained under serum-free culture conditions
demonstrated that SW480 and SW620 cells did not respond to LPS
stimulation. In contrast, LPS in the presence of recombinant sCD14
activated NF-
B, up-regulated
1 integrin
expression, and promoted tumor cell adhesion and invasion. Thus, the
apparent function of sCD14 is to enable tumor cells that lack mCD14 to
recognize and respond to LPS. Furthermore, LPS at 0.1 µg/ml, an
optimal dose according to the preliminary dose-response experiments
(data not shown), was sufficient to cause SW480 and SW620 cell
activation. These results are consistent with previous studies in which
endothelial cells can be activated by high concentrations of LPS
(50500 ng/ml) in the presence of sCD14, whereas low concentrations of
LPS (510 ng/ml) require the presence of LBP for sCD14-dependent
activation (45).
Different subunits of
1 integrin and various
levels of their expression have been found in different types of tumor
cells. Forexample, human hepatocellular carcinoma cell lines,
PLC/PRF/5, Hep3B, HepG2, HLE, HuH7, and C3A cells, constitutively
express high levels of
1 and
6 subunits and various low levels of
1,
2,
3, and
5 subunits, whereas expression of the
4 subunit is absent in each cell line
(50). We found that the predominant adhesion receptors in
SW480 cells were the
1
1,
2
1, and
4
1 integrins; that
2
1,
4
1, and
6
1 integrins were
highly expressed in SW620 cells; and that the
3
1 and
5
1 integrins were
undetectable in either cell line. It has been found that overexpression
of integrin
v
3
correlates with aggressive phenotypes in different malignancies and
with tumor angiogenesis (51, 52). However, neither SW480
nor SW620 cells expressed
v
3. The various
levels of
1 integrin expression on SW480 and
SW620 cells may represent a low constitutive activity of different
1 integrin subunits, which may account for
spontaneous adhesion of tumor cells to fibronectin, collagen I, and
laminin, and invasion in Matrigel as observed in the present study.
It is notable that LPS stimulation in the presence of sCD14 resulted in
the up-regulation of
1 integrin expression in
SW480 and SW620 cells. LPS-modulated
1
integrin expression appears to be both subunit and cell specific, as
LPS significantly enhanced the expression of
1,
2,
4, and
6 subunits,
but had no effect on
1 expression on SW480
cells or
2 expression on SW620 cells. In
contrast, a stimulatory anti-
1 mAb TS2/16
has been found to induce a rapid activation of
1 integrin as confirmed by an enhanced cell
adhesion to collagen, but it does not change the expression of
different
1 integrin subunits (50, 53). Increased expression of
1 integrin
is thought to be associated with the ability of tumor cells to interact
with the extracellular matrix and to subsequently form an
organ-specific metastatic colonization through
1 integrin-mediated cell adhesion and
invasion. For example, TGF-
1 stimulates the
hepatocellular carcinoma cell line SMMC-7721 cell adhesion to
extracellular matrix through up-regulation of
5
1 integrin
expression (54). Furthermore, blockade of the
3 subunit prevents breast carcinoma cell line
MDA-MB-231 cell migration and invasion (10).
4-
CYT-transfected MDA-MB-435 cells that
are deficient in forming the
6
1 heterodimer are
unable to establish metastatic foci in lungs (11).
Importantly, the present study has demonstrated that LPS stimulation
significant enhances tumor cell attachment to extracellular matrix
proteins and promotes tumor cell invasion, indicating a direct and
distinct effect of LPS on the invasive and metastatic ability of tumor
cells. By using
1 integrin function-blocking
mAbs, we further demonstrated that LPS-mediated tumor cell adhesion and
invasion correlated with an increased expression of
1 integrins, as 4B4 and 6S6 strongly inhibited
LPS-induced tumor cell adhesion and invasion. The process of tumor cell
invasion involves cell attachment to the subendothelial extracellular
matrix and subsequent unidirectionally cell migration coupled with
local proteolysis induced by a number of degradative enzymes,
particularly matrix metalloproteinases (MMP). It has been shown that
increased activity of
1 integrin subunits
results in MMP production and the activation of MMP proenzymes
(10, 55). Although we did not measure MMP directly in the
present study, the enhanced tumor cell invasion may correlate with the
release and activation of MMP that could be mediated by increased
1 integrin activity or by LPS stimulation
directly. We have previously shown that endotoxin or LPS contamination
of the peritoneal cavity and systemic endotoxemia are involved in
surgically induced lung metastases of 4T1 mammary adenocarcinoma cells
in mice, which correlates with an elevation in circulating levels of
VEGF and an increased cell mitosis/apoptosis ratio in metastatic tumor
burden (22). Results from this study provide further
evidence for a direct effect of LPS on tumor cell adhesion to and
invasion into the extracellular matrix.
Constitutive activation of NF-
B has been described in a number of
tumor cells, and appears to be associated with continued cytokine
production, inhibition of apoptosis, activation of cell cycle, and
possibly tumor progression (56). A low level of
constitutive activation of NF-
B was also found in SW480 and SW620
cells, which may account for an overproduction of VEGF by these cells
in standardized culture conditions (data not shown). In the present
study it is interesting to find that LPS stimulation of tumor cells
resulted in a marked increase in NF-
B-DNA binding activity. To
examine the correlation between NF-
B activation and LPS-induced
tumor cell metastatic potential, SN50, a synthetic peptide that blocks
NF-
B signaling by inhibition of nuclear translocation of NF-
B
(40), and a dominant negative I
B-
vector, which
prevents NF-
B activation in transfected cells (41),
were used in additional experiments. Blockade of NF-
B activation by
either SN50 or I
B-
transfection abrogated LPS-induced
1 integrin overexpression and attenuated tumor
cell adhesion and invasion, indicating that NF-
B activation is a
prerequisite not only for the transduction of LPS signals in tumor
cells, but also for the enhanced tumor cell metastatic ability induced
by LPS stimulation. LPS-mediated NF-
B activation in the tumor cells
switches the target gene to transcribe and synthesize new adhesion
molecules, including
1 integrins. Increased
surface expression of
1 integrins mediates
tumor cell adhesion to ligands in the extracellular matrix, which
elicits a variety of intracellular signals, including NF-
B
activation (57, 58), a positive feedback loop that could
occur to sustain enhanced levels of NF-
B activity. Activated NF-
B
has been found to stimulate the production of a number of degradative
enzymes, such as MMP and urokinase-like plasminogen activator
(59, 60), which, together with
1
integrin, results in tumor cell invasion. Blockade of NF-
B signaling
has been shown to result in the down-regulation of MMP9 and heparanase
and the up-regulation of tissue inhibitors of matrix
metalloproteinases, thus preventing tumor cell intravasation and lung
metastases (33). Taken together, these reports suggest
NF-
B to be an important regulator of the metastatic phenotype, and
the up-regulation of NF-
B in tumor cells induced by LPS in this
study could have significant effects on metastatic potential.
Two recent studies have reported that commercially available LPS is
contaminated by microbial proteins such as bacterial lipoprotein, as
repurification of commercial preparations of LPS results in
TLR4-mediated, but not TLR2-mediated, cellular activation (61, 62). Although we cannot completely exclude the possibility that
LPS used in this study was contaminated with non-LPS bacterial cell
wall components, it must be pointed out that LPS from any bacterial
species is a mixture of different LPS, which may elicit distinct
biological effects (63, 64), and that repurification of
LPS by repeated phenol extraction may preferentially concentrate
certain LPS subsets more than others. Further work will be required to
confirm the effect of pure LPS on tumor cell activation. Furthermore,
although this study has demonstrated the activation of NF-
B by LPS
through a CD14-dependent mechanism, the signal transduction pathways of
LPS in tumor cells are largely unexplored.
In conclusion, LPS or endotoxin released by Gram-negative
bacteria may have a direct effect on tumor progression by
promoting tumor cell adhesion and invasion. This effect is mediated by
LPS-induced up-regulation of
1 integrin and
activation of NF-
B. These findings further implicate LPS, introduced
by surgical procedures such as laparotomy, as a causative factor in
surgically induced tumor metastatic growth. Therefore, neutralization
of LPS and modulation of NF-
B may be considered therapeutic
strategies for the prevention of tumor relapse and metastasis in
perioperative surgical practice.
| Footnotes |
|---|
2 Abbreviations used in this paper: LBP, LPS-binding protein; mCD14, membrane-bound CD14; MMP, matrix metalloproteinase; sCD14, soluble CD14; TLR, Toll-like receptor; VEGF, vascular endothelial growth factor. ![]()
Received for publication May 15, 2002. Accepted for publication November 26, 2002.
| References |
|---|
|
|
|---|
2
1 integrin cell-surface expression protects A431 cells from epidermal growth factor-induced apoptosis. Int. J. Cancer 87:360.[Medline]
3
1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int. J. Cancer 87:336.[Medline]
6
1 promotes the survival of metastatic human breast carcinoma cells in mice. Am. J. Pathol. 151:1191.[Abstract]
6 messenger RNA overexpression in hepatocellular carcinoma. Hepatology 22:1447.[Medline]
B: ten years after. Cell 87:13.[Medline]
B kinase complex. Mol. Cell. Biol. 19:4547.
B
is necessary for activation of transcription factor NF-
B. Nature 365:182.[Medline]
B in hepatocellular carcinoma. Cancer 89:2274.[Medline]
B/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest. 100:2952.[Medline]
B sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis. Ann. Thorac. Surg. 70:930.
B and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. Cancer Res. 59:3495.
B activation is related to the resistance of lung cancer cells to TNF-
-induced apoptosis. Biochem. Biophys. Res. Commun. 273:140.[Medline]
B. Nat. Med. 5:412.[Medline]
B. Cancer Res. 60:6557.
4 subunit of the integrin VLA-4: distinct effects on adhesion to CS1/fibronectin, VCAM-1 and invasion. J. Cell Biol. 123:245.
B by tumor necrosis factor but not interleukin-1 in human endothelial cell line ECV304. J. Biol. Chem. 272:25941.
B-
is associated with prolonged NF-
B activity in human glial cells. J. Biol. Chem. 275:39996.
B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J. Biol. Chem. 270:14255.
B-mediated inhibition of apoptosis is required for encephalomyocarditis virus virulence: a mechanism of resistance in p50 knockout mice. J. Virol. 72:5654.